MDL Track
MDL 3163
E.D. Pa.
GLP-1 receptor agonist NAION/vision-loss track
54 pending
Pharmaceutical · litigation and safety scrutiny around semaglutide products and non-arteritic anterior ischemic optic neuropathy
Defendant
Novo Nordisk A/S
MDL / Track
MDL 3163
E.D. Pa.
Judge
Judge Karen S. Marston
Plaintiffs
roughly 93 pending actions (54 per JPML's March 2, 2026 report, plus ~39 new filings tracked since)
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Federal NAION cases against Novo Nordisk and Eli Lilly are centralized in MDL No. 3163 before Judge Karen Spencer Marston in the Eastern District of Pennsylvania, with 216 pending actions as of September 2026. On July 2, 2026, Judge Marston issued Case Management Order No. 12 directing early discovery and motion practice on general causation and warning adequacy. Plaintiffs allege semaglutide, tirzepatide, and other GLP-1 drugs cause non-arteritic anterior ischemic optic neuropathy and that manufacturers failed to warn; defendants dispute causation and note diabetes and obesity are independent risk factors.
Causation Theory
The European Medicines Agency's safety committee concluded in June 2025 that semaglutide roughly doubles NAION risk in adults with type 2 diabetes, estimating one additional case per 10,000 person-years, and advised discontinuation if NAION is confirmed. A September 2026 network meta-analysis in Diabetes, Obesity and Metabolism found semaglutide carried the highest NAION risk among GLP-1RAs (HR 1.538, 95% CI 1.305–1.816), with FAERS data showing a strong disproportionate reporting ratio, and identified CASP3 binding and neurodegeneration pathways as potential mechanisms. Observational studies remain mixed: a 2024 JAMA Ophthalmology study by Hathaway et al. reported elevated risk, while a 2026 pooled analysis of 96,829 participants in randomized placebo-controlled trials found no increased incidence versus placebo.
Case Management Orders
Litigation status
MDL No. 3163 is proceeding before Judge Karen S. Marston in the Eastern District of Pennsylvania with early discovery and motion practice focused on general causation and warning adequacy following Case Management Order No. 12 entered July 2, 2026. A Science Day was held June 2, 2026, and the court is pushing threshold science-and-label questions before individual bellwether selection.
MDL Track
MDL 3163
E.D. Pa.
GLP-1 receptor agonist NAION/vision-loss track
54 pending
State Court Activity
New Jersey multicounty litigation consolidated in Bergen County under Superior Court Judge Gregg A. Padovano; parallel track to federal MDL
MDL 3163 Leadership
Plaintiff Leadership
Co-Chair, Plaintiffs' Executive Committee & Federal–State Court Liaison
Co-Lead Counsel for Plaintiffs
Member, Plaintiffs' Executive Committee
Geographic exposure
Global pharmacovigilance analysis shows semaglutide disproportionately associated with ischemic optic neuropathy events (ROR=21.37), with formulation-dependent risk: Wegovy (ROR=74.89), Ozempic (ROR=18.81). EMA estimates 'very rare' incidence up to 1 in 10,000. Clinical trial pooled analysis (96,829 participants, 205,777 patient-years) found no increased incidence versus placebo, creating causation battleground.
MDL No. 3163 (In re: GLP-1 NAION Products Liability Litigation) before Judge Karen Spencer Marston; 110 pending federal cases as of June 2026 per docket filings
New Jersey Supreme Court approved multicounty litigation for NAION vision loss claims; nearly 100 lawsuits filed since 2025 per court records; Novo Nordisk headquartered in state
Novo Nordisk semaglutide API manufacturing facility; FDA May 2022 inspection found quality control lapses including B. cepacia contamination in drug product samples (Reuters, Sept. 20, 2023)
Illustrative case: 62-year-old male prescribed Ozempic 2023, diagnosed with NAION four months later, now blind in both eyes; lawsuit filed April 2025
EMA Pharmacovigilance Risk Assessment Committee concluded June 2025 that NAION is 'very rare' side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy); labeling updated; did not extend to tirzepatide (Zepbound/Mounjaro)
Therapeutic Goods Administration updated class warnings July 23, 2026 for all GLP-1 receptor agonists due to NAION risk; urgent medical care advised for sudden vision loss
UK regulator updated semaglutide prescriber and patient guidance following EMA review
Key defendants
Novo Nordisk A/S
Role: Manufacturer
Primary defendant in MDL 3163 (In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation), consolidated in E.D. Pa. before Judge Karen Marston. Core exposure on failure-to-warn for Ozempic/Wegovy NAION risk. EMA June 2025 labeling change for NAION as 'very rare' adverse reaction strengthens causation arguments.
Novo Nordisk Inc.
Role: Manufacturer
U.S. subsidiary named in MDL 3163 and New Jersey MCL applications. Same litigation posture as parent—early pretrial proceedings with focus on prescriber information and FDA FAERS data on vision loss reports.
Eli Lilly and Company
Role: Manufacturer
Named defendant in MDL 3163 for Trulicity, Mounjaro, Zepbound. Lilly urged JPML to consolidate NAION cases into existing gastroparesis MDL rather than separate MDL; panel rejected this. Lower case volume than Novo Nordisk in NAION track but same failure-to-warn theory.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Novo Nordisk A/S | Manufacturer | Primary defendant in MDL 3163 (In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation), consolidated in E.D. Pa. before Judge Karen Marston. Core exposure on failure-to-warn for Ozempic/Wegovy NAION risk. EMA June 2025 labeling change for NAION as 'very rare' adverse reaction strengthens causation arguments. |
| Novo Nordisk Inc. | Manufacturer | U.S. subsidiary named in MDL 3163 and New Jersey MCL applications. Same litigation posture as parent—early pretrial proceedings with focus on prescriber information and FDA FAERS data on vision loss reports. |
| Eli Lilly and Company | Manufacturer | Named defendant in MDL 3163 for Trulicity, Mounjaro, Zepbound. Lilly urged JPML to consolidate NAION cases into existing gastroparesis MDL rather than separate MDL; panel rejected this. Lower case volume than Novo Nordisk in NAION track but same failure-to-warn theory. |
Timeline
JAMA Study Links Semaglutide to NAION
JAMA Ophthalmology publishes retrospective study reporting association between semaglutide prescriptions and increased NAION risk in neuro-ophthalmology referral population. Study limitations include specialized setting restricting generalizability.
FDA Flags NAION as Potential Safety Issue
FDA adverse-event monitoring program lists NAION as potential serious safety issue for GLP-1 receptor agonist class in October-December 2024 quarterly review, stating it was evaluating whether regulatory action was necessary.
EMA Concludes NAION Is Semaglutide Side Effect
European Medicines Agency Pharmacovigilance Risk Assessment Committee concludes NAION is a very rare adverse effect of semaglutide, estimating frequency up to approximately 1 case per 10,000 treated and two-fold relative increase in NAION among adults with type 2 diabetes taking semaglutide; recommends product-information update for Ozempic, Wegovy and Rybelsus.
WHO Issues Medical Product Alert
World Health Organization follows EMA with medical product alert on semaglutide and NAION risk.
EU Label Updated for NAION
Denmark's compensation body records EU label change entering NAION into side-effect section for Wegovy, Ozempic and Rybelsus product information.
New Jersey Supreme Court Creates NAION MCL
New Jersey Supreme Court grants application consolidating semaglutide NAION cases as multicounty litigation in Bergen County under Superior Court Judge Gregg A. Padovano, separate from gastrointestinal injury track.
JPML Creates MDL No. 3163
U.S. Judicial Panel on Multidistrict Litigation creates MDL No. 3163, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, centralizing federal NAION cases in Eastern District of Pennsylvania before Judge Karen S. Marston; panel deliberately separates from gastrointestinal MDL No. 3094. Transfer Order Doc. 49.
UK MHRA Issues Drug Safety Update
UK Medicines and Healthcare products Regulatory Agency Drug Safety Update reports three spontaneous Yellow Card reports suggestive of NAION with semaglutide between 2018 and 1 August 2025 against 10.2 million packs dispensed in five years; advises urgent referral and discontinuation if NAION confirmed.
Science Day Held in MDL 3163
Judge Marston holds non-adversarial Science Day in MDL No. 3163 where parties present medical and scientific evidence on GLP-1 drugs and NAION; transcripts barred from use as evidence or for impeachment at trial per Case Management Order No. 6.
Judge Marston Orders Early Causation Discovery
Judge Marston enters Case Management Order No. 12 in MDL No. 3163 directing early discovery and motion practice on general causation and warning adequacy, accelerating threshold science-and-label questions before bellwether selection.
Australia TGA Updates Class Warnings
Australia's Therapeutic Goods Administration announces updated GLP-1 class warnings due to NAION potential, advising health professionals to instruct patients to seek urgent care for sudden or partial vision loss.
MDL 3163 Reaches 216 Pending Actions
JPML monthly statistics report records 216 actions pending in MDL No. 3163 as of September 1, 2026, on actions-pending basis.
Statute of limitations
NAION cases centralized in MDL 3163, In Re: Semaglutide (Ozempic, Wegovy) Products Liability Litigation, S.D. Fla., per JPML 2025 order. Discovery accrual likely runs from NAION diagnosis date or July 2024 Harvard/JAMA Ophthalmology study publication establishing semaglutide-NAION association. EMA concluded June 2025 that NAION should be listed as very rare adverse reaction for semaglutide products. Exclude MDL 3094 (GI track) per guidance. No federal preemption holding in NAION track.
Florida
4 years from discovery
Rule: Fla. Stat. § 95.11(3)(a) products liability; discovery rule applies
Discovery: Accrues when plaintiff knew or should have known of injury and its likely cause; NAION diagnosis date or July 2024 Harvard/JAMA study publication may trigger
MDL 3163 centralized in S.D. Fla. per JPML 2025 order; early pretrial proceedings as of March 2026
Pennsylvania
2 years from discovery
Rule: 42 Pa. C.S. § 5524(2); discovery rule applies
Discovery: Accrues when plaintiff discovers or reasonably should discover injury and causal connection; NAION cases may accrue at diagnosis or regulatory recognition
MDL 3094 (GI track) presided over by Judge Karen S. Marston in E.D. Pa.; NAION cases now in MDL 3163 (S.D. Fla.) per JPML 2025 order
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 340.3; discovery rule applies
Discovery: Accrues when plaintiff suspects or should suspect injury caused by defendant's conduct
Large plaintiff pool; EMA August 2024 labeling change for NAION risk may support discovery arguments
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies
Discovery: Accrues when injury becomes inherently undiscoverable and not discoverable by reasonable diligence; NAION sudden onset favors plaintiffs
New York
3 years from discovery
Rule: N.Y. C.P.L.R. § 214(5); discovery rule applies
Discovery: Accrues when plaintiff discovers or should have discovered injury and its cause; July 2024 study date critical for recent users
Federal filings from N.Y. transferred to MDL 3163 (S.D. Fla.)
New Jersey
2 years from discovery
Rule: N.J. Stat. § 2A:14-2; discovery rule applies
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its cause
Multicounty litigation (MCL) application pending for NAION claims against Novo Nordisk; state court alternative to federal MDL 3163
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Florida | 4 years from discovery | Fla. Stat. § 95.11(3)(a) products liability; discovery rule applies | Accrues when plaintiff knew or should have known of injury and its likely cause; NAION diagnosis date or July 2024 Harvard/JAMA study publication may trigger | MDL 3163 centralized in S.D. Fla. per JPML 2025 order; early pretrial proceedings as of March 2026 |
| Pennsylvania | 2 years from discovery | 42 Pa. C.S. § 5524(2); discovery rule applies | Accrues when plaintiff discovers or reasonably should discover injury and causal connection; NAION cases may accrue at diagnosis or regulatory recognition | MDL 3094 (GI track) presided over by Judge Karen S. Marston in E.D. Pa.; NAION cases now in MDL 3163 (S.D. Fla.) per JPML 2025 order |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 340.3; discovery rule applies | Accrues when plaintiff suspects or should suspect injury caused by defendant's conduct | Large plaintiff pool; EMA August 2024 labeling change for NAION risk may support discovery arguments |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies | Accrues when injury becomes inherently undiscoverable and not discoverable by reasonable diligence; NAION sudden onset favors plaintiffs | — |
| New York | 3 years from discovery | N.Y. C.P.L.R. § 214(5); discovery rule applies | Accrues when plaintiff discovers or should have discovered injury and its cause; July 2024 study date critical for recent users | Federal filings from N.Y. transferred to MDL 3163 (S.D. Fla.) |
| New Jersey | 2 years from discovery | N.J. Stat. § 2A:14-2; discovery rule applies | Accrues when plaintiff knows or reasonably should know of injury and its cause | Multicounty litigation (MCL) application pending for NAION claims against Novo Nordisk; state court alternative to federal MDL 3163 |
Live intelligence
AI litigation brief
Ozempic NAION remains early-stage / active mdl with 135 current signals in the accepted feed.
Overview
MDL No. 3163 is proceeding before Judge Karen S. Marston in the Eastern District of Pennsylvania with early discovery and motion practice focused on general causation and warning adequacy following Case Management Order No. 12 entered July 2, 2026. A Science Day was held June 2, 2026, and the court is pushing threshold science-and-label questions before individual bellwether selection.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3163, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3163 should stay on the lead docket watch because it is the primary consolidation vehicle for Ozempic NAION.
Generated Sep 30, 2026, 10:00 AM UTC
135 events detected
Google News (62)
FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning - inkl
GLP-1 companies face flurry of lawsuits after consumers say drugs caused vision loss - MassLive
Mass. man joins lawsuit claiming Ozempic made him go blind - MassLive.com
Ozempic blindness lawsuit: Dedham man joins legal battle - MassLive
U.S. Patients Sue Drugmakers Over Vision Loss Linked to Ozempic, Wegovy - Seoul Economic Daily
Rare vision-loss condition linked to GLP-1 drugs like Ozempic and Wegovy under review - chicagostarmedia.com
Hundreds of Lawsuits Allege Ozempic and Other GLP-1 Drugs Caused Sudden Vision Loss, but Absolute Risk Appears Low - Medical Daily
Some GLP-1 companies facing lawsuits over vision loss. What to know - WBAL-TV
Some GLP-1 companies facing lawsuits over vision loss. What to know - KCRA
Lawsuits claim popular GLP-1 drugs linked to vision loss - KTALnews.com
Makers of Ozempic and Other GLP-1 Drugs Face Hundreds of Lawsuits Over Sudden Vision Loss - Complex
Eli Lilly Sued Over NAION Claim? Lawsuits Against The Three GLP-1 Makers Explained - Mashable India
Ozempic, Wegovy and Mounjaro face US lawsuits over rare vision-loss risk - africanews.com
Ozempic, Mounjaro face lawsuits in the US over vision loss. What's the risk? - India Today
Can Ozempic Cause Blindness? Dozens Sue Over Alleged Link to Rare 'Eye Stroke' Condition - inkl
Ozempic, Wegovy And Zepbound May Cause Vision Loss? Indian Doctors Say Patients Need Not Panic - ndtv.com
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients - NewsNation
Ozempic, Wegovy, Zepbound sued for sudden vision loss and blindness risk: Can GLP-1 drugs cause blindness - The Times of India
Patients claim popular GLP-1 drugs led to permanent vision loss - NewsNation
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss - AZ Family
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy and Mounjaro caused permanent vision loss - WDTV 5
Dozens sue over 'eye stroke' tied to GLP-1 weight-loss drugs - moneywise.com
Woman Details Losing Vision in 1 Eye After Taking GLP-1 As Hundreds of Patients Sue Drug Companies - TODAY.com
Woman Details Losing Vision After Taking GLP-1 As Hundreds of Patients Sue Drug Companies - TODAY.com
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss - Fox News
GLP-1 Vision Loss Lawsuits: What the Science Says So Far - Charlotte Observer
Patients sue GLP-1 makers over sudden loss of vision - The Hill
Can GLP-1 drugs like Ozempic cause vision loss? What we know about the risk - Al Jazeera
The Terrifying Vision Side Effect At The Center Of A Growing Ozempic Legal Battle - The Daily Wire
Could GLP‑1 drugs be causing blindness? Arizona lawsuits are growing - azcentral.com and The Arizona Republic
GLP-1 Drugmakers Face Lawsuits as Patients Claim Ozempic and Wegovy Led To Rare Permanent Vision Loss - inkl
Could GLP-1s be linked to a rare type of vision loss? Here’s what to know. - The Boston Globe
Lawsuits raise questions about possible GLP-1 link to rare vision loss - 41NBC News
Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION? - Health and Me
Why Are Ozempic, Wegovy and Mounjaro Lawsuits Claiming Rare Vision Loss? - LatestLY
What GLP-1 users should know about the potential risk of a rare type of vision loss - ABC News - Breaking News, Latest News and Videos
Are GLP-1s causing blindness? What we know about rare cases - USA Today
"Ozempic, Wegovy Injections Linked to Vision Loss: U.S. Patients File Lawsuits" - 아시아경제
US Patients File Lawsuits Against Drugmakers Over Vision Loss Allegedly Linked to Ozempic, Wegovy - news.sbs.co.kr
"Lost Vision After Wegovy and Ozempic: U.S. Patients File Lawsuits Over Sudden Sight Loss While Trying to Lose Weight" - 아시아경제
Patients File Lawsuits After Experiencing Sudden Vision Loss Following Wegovy Use - news.sbs.co.kr
Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss - WSJ
'You Wake Up and You're Blind' — The Scary GLP-1 Lawsuits Every Ozempic & Wegovy User Should Know About - MadameNoire
Parker Waichman Client Shares Story of GLP-1-Related Vision Loss with FOX Boston 25 News - PR Newswire
Lawsuit claims link between GLP-1 weight loss drugs and blindness - Boston 25 News
Can GLP-1 Medications Like Ozempic Affect Your Vision? - US News Health
Parker Waichman Applauds Health Canada and Australia for Strengthening NAION Safety Guidance for Certain GLP-1 Medications - PR Newswire
Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic - The Guardian
Australia's TGA issues safety alert over rare vision loss risk from Ozempic - Jang
Australian regulator warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic - The Guardian
Australia Issues Urgent Eye Stroke Warning for Ozempic and Wegovy Patients - streamlinefeed.co.ke
New warning for Ozempic, Wegovy and Mounjaro over serious eye disorder including blindness - 7NEWS
newsGP - TGA issues GLP-1 RA class-wide safety update - racgp.org.au
newsGP - TGA issues GLP-1 RA class-wide safety update - Royal Australian College of General Practitioners (RACGP)
Rare eye disorder linked to Ozempic-like medications - abc.net.au
Rare eye disorder linked to Ozempic-like medications - ABC News & Headlines – Australian Broadcasting Corporation
Parker Waichman LLP Comments on Growing Public Attention Surrounding GLP-1 Vision Loss Litigation - PR Newswire
Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV
Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds - Health and Me
New Analysis Links Wegovy to a Rare Eye Condition That Can Cause Sudden, Permanent Vision Loss - Medical Daily
Ozempic Blindness: Should You Worry? - GoodRx
Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning - Dallas Express
Irish medical journal • Khan MS • PMID 42808150 • Case Reports.
Diabetes, obesity & metabolism • Huang T • PMID 42768849 • Journal Article.
Korean journal of family medicine • Kim WJ • PMID 42773534 • Case Reports.
Biomolecules & biomedicine • Akhtar S • PMID 42770962 • Journal Article.
Clinical & experimental optometry • Saatci AO • PMID 42680170 • Journal Article.
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket filed in JPML: Plaintiffs are suing Defendants because they failed to provide adequate warnings regarding the risk of permanent vision loss associated with their medications. Plaintiffs claim that the use of Ozempic and Mounjaro led to the development of non-arteritic anterior ischemic optic neuropathy (NAION). Th
Anti-Discrimination and Harassment Notice
This is an administrative notice about anti-discrimination policies and reporting procedures, not a substantive court order.
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against NOVO NORDISK A/S, NOVO NORDISK INC., ( Filing fee $ 405 receipt number APAEDC-19692834.), filed by STEPHEN ZITO. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 09/29/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against ELI LILLY AND COMPANY, LILLY USA, LLC ( Filing fee $ 405 receipt number APAEDC-19692707.), filed by DEBRA KLEIN. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 09/29/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against ELI LILLY AND COMPANY, LILLY USA, LLC ( Filing fee $ 405 receipt number APAEDC-19692476.), filed by JAMES BROADWAY, JR. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 09/29/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against ELI LILLY AND COMPANY, LILLY USA LLC ( Filing fee $ 405 receipt number APAEDC-19691842.), filed by GARY STOCCO. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Silverman, Craig) (Entered: 09/29/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT Mark David Hansen against All Defendants ( Filing fee $ 405 receipt number APAEDC-19691330.), filed by Mark David Hansen. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(ORENT, JONATHAN) (Entered: 09/29/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT Laurie Beth Frazier against All Defendants ( Filing fee $ 405 receipt number APAEDC-19687399.), filed by Laurie Beth Frazier. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(ORENT, JONATHAN) (Entered: 09/28/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against NOVO NORDISK A/S, NOVO NORDISK, INC. ( Filing fee $ 405 receipt number APAEDC-19687039.), filed by JEFFERY HALL. (Attachments: # 1 Civil Cover Sheet)(Theodore, Mitchell) (Entered: 09/28/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19683148.), filed by WELDON GANSKY. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Benton, Danae) (Entered: 09/25/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 10:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
135
events detected
AI Brief
Ozempic NAION remains early-stage / active mdl with 135 current signals in the accepted feed.
Overview
MDL No. 3163 is proceeding before Judge Karen S. Marston in the Eastern District of Pennsylvania with early discovery and motion practice focused on general causation and warning adequacy following Case Management Order No. 12 entered July 2, 2026. A Science Day was held June 2, 2026, and the court is pushing threshold science-and-label questions before individual bellwether selection.
Key developments
PACER court filing on Dec 31: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation. ‖ inkl news on Sep 29: FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning - inkl. ‖ openFDA recall on Jul 29: FDA Recall: SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL . ‖ PubMed research on Sep 28: Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use..
Generated Sep 30, 2026, 10:00 AM UTC
Tracked MDLs
MDL 3163
E.D. Pa.
GLP-1 receptor agonist NAION/vision-loss track